From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs

From molecular promise to preclinical results: HDAC inhibitors in the race for healthy aging drugs

Abstract Reversing or slowing the aging process brings great promise to treat or prevent age‐related disease, and targeting the hallmarks of aging is a strategy to achieve this. Epigenetics affects several if not all of the hallmarks of aging and has therefore emerged as a central target for interve...

Full description

Saved in:
Bibliographic Details
Main Authors: Rebecca L McIntyre, Eileen G Daniels, Marte Molenaars, Riekelt H Houtkooper, Georges E Janssens
Format: Article
Language:English
Published: Springer Nature 2019-08-01
Series:EMBO Molecular Medicine
Subjects:
epigenetics
geroprotector
hallmarks of aging
HDAC inhibitors
preclinical models
Online Access:https://doi.org/10.15252/emmm.201809854
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.15252/emmm.201809854

Similar Items